RxDoctor Payments Data

Kelly Nelson, MD

Internal Medicine · Westbrook, CTNPI 1659396737

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 82 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$184
  • Boehringer Ingelheim$182
  • Amarin Pharma, Inc.$120
  • Sanofi-aventis U.S. LLC$106
  • AstraZeneca$70
  • E.r. Squibb & Sons, L.L.C.$60
  • plus $385 from 12 others

What the payments were for

  • Food & beverage$1,03994%
  • Education$676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,107 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$126,601
Medicare patients
265
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$196,401
EliquisApixaban99$126,748
JardianceEmpagliflozin33$54,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,893
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$23,924
TrintellixVortioxetine Hydrobromide17$10,623
Tresiba Flextouch U-200Insulin Degludec11$9,252
Atorvastatin Calcium845$8,995
Tresiba Flextouch U-100Insulin Degludec12$6,441
Spiriva HandihalerTiotropium Bromide12$5,988
Breo ElliptaFluticasone/Vilanterol12$4,743
Rosuvastatin Calcium212$3,661
Amlodipine Besylate422$3,210
SynthroidLevothyroxine Sodium60$3,007
Albuterol Sulfate HfaAlbuterol Sulfate91$2,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$184$196,401113 claims
PfizerEliquis$55$126,74899 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$14$60,56070 claims
Boehringer IngelheimJardiance$182$54,91033 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$43$10,62317 claims
AbbVieSynthroid$20$3,00760 claims
Scilex Pharmaceuticals Inc.Colchicine$18$91830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Westbrook

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →